Coherus Oncology Inc Dossier
Qualitative Analysis
Business overview
Coherus Oncology, Inc. (formerly Coherus BioSciences, Inc.) is a commercial-stage biopharmaceutical company headquartered in Redwood City, California. The company has strategically pivoted from its biosimilar origins to become a pure-play innovative oncology firm. Its commercial anchor is LOQTORZI® (toripalimab-tpzi), a next-generation PD-1 inhibitor and the only FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC). Coherus is actively developing a diversified pipeline of next-generation immuno-oncology therapies targeting the tumor microenvironment to extend patient survival across difficult-to-treat tumor types.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the divestiture of its biosimilar franchises (including UDENYCA), the company rebranded from Coherus BioSciences, Inc. to Coherus Oncology, Inc. to align exclusively with developing and commercializing proprietary immuno-oncology medicines.
Expected impact: Eliminates low-margin biosimilar commercialization costs, reduces headcount by approximately 35% (from 228 to 147 employees), and focuses resources on high-margin proprietary combination therapies.
Accelerating the commercial launch and market penetration of LOQTORZI (toripalimab-tpzi) in its FDA-approved indication for recurrent or metastatic nasopharyngeal carcinoma (NPC).
Expected impact: Aims to capture approximately 70% market share in NPC, translating to a peak annual run rate of $175 million to help fund internal pipeline operations.
Advancing novel mechanistic combinations of the foundational PD-1 inhibitor LOQTORZI with internal pipeline candidates, specifically casdozokitug (IL-27 antagonist) and tagmokitug (anti-CCR8 cytolytic antibody).
Expected impact: Unlocks immune resistance to current therapies, expands LOQTORZI's addressable indications into major solid tumors (HCC, HNSCC, gastric, colorectal), and drives proprietary combination synergies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Surface Oncology to bolster Coherus's innovative immuno-oncology pipeline, adding key clinical-stage assets including casdozokitug (IL-27 targeting antibody) and tagmokitug (CHS-114, CCR8-targeting antibody) previously valued at over $950 million.
Financial impact: Significantly expanded the proprietary pipeline with mid-stage assets, positioning the company for long-term growth beyond its foundational PD-1 inhibitor.
Strategic Partnerships
Divestment of the UDENYCA (pegfilgrastim-cbqv) biosimilar franchise to transition exclusively into an innovative oncology company and dramatically reduce debt.
Terms: Total transaction value of up to $558.4 million, including an upfront cash payment of $483.4 million (received at close in April 2025) and eligibility for up to $75 million in future sales-based milestone payments.
Co-development and exclusive commercialization rights for LOQTORZI (toripalimab-tpzi) in the United States and Canada.
Terms: Coherus leads commercialization in the US and Canada, utilizing LOQTORZI as the foundational PD-1 backbone for its proprietary combination pipeline.
Exploring the combination of Coherus's anti-CCR8 antibody tagmokitug (CHS-114) with J&J's pasritamig (a T-cell engager) in patients with prostate cancer.
Terms: Collaborative clinical cohort evaluation with active patient accrual in 2026.